{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:36:55Z","timestamp":1764020215115,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.eplepsyres.2018.07.011","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T14:13:57Z","timestamp":1532355237000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antiepileptic drug prescription in Dutch children from 2006\u20132014 using pharmacy-dispensing data"],"prefix":"10.1016","volume":"146","author":[{"given":"Amerins","family":"Weijenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens H.J.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina C.M.","family":"Schuiling-Veninga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-3188","authenticated-orcid":false,"given":"Oebele F.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2447-7746","authenticated-orcid":false,"given":"Petra M.C.","family":"Callenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3908","article-title":"Incidence and prevalence of childhood epilepsy: a nationwide cohort study","volume":"139","author":"Aaberg","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4016","article-title":"Short-term seizure outcomes in childhood epilepsy","volume":"141","author":"Aaberg","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2006.02842.x","article-title":"Prioritizing children\u2019s medicines for research: a pharmaco-epidemiological study of antiepileptic drugs","volume":"63","author":"Ackers","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.17712\/nsj.2016.3.20150766","article-title":"Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan","volume":"21","author":"Albsoul-Younes","year":"2016","journal-title":"Neurosciences (Riyadh)"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/archdischild-2012-302822","article-title":"Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline","volume":"97","author":"Appleton","year":"2012","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11096-013-9755-2","article-title":"Evaluation of unlicensed and off-label antiepileptic drugs prescribed to children: Brazilian Regulatory Agency versus FDA","volume":"35","author":"Borges","year":"2013","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40272-015-0139-z","article-title":"Comparison of drug utilization patterns in observational data: antiepileptic drugs in pediatric patients","volume":"17","author":"Bourgeois","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40272-015-0147-z","article-title":"Trends in antiepileptic drug prescriptions for childhood epilepsy at a tertiary children\u2019s hospital in Korea, 2001-2012","volume":"17","author":"Cho","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00148581-200810040-00003","article-title":"Use of second-generation antiepileptic drugs in the pediatric population","volume":"10","author":"Chung","year":"2008","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1440-1754.2011.02223.x","article-title":"Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines","volume":"48","author":"Cohen","year":"2012","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0055","unstructured":"College ter beoordeling van geneesmiddelen 2018. www.cbg-meb.nl (Accessed June 2018)."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2012.06.008","article-title":"Treatment of paediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs","volume":"103","author":"Dorks","year":"2013","journal-title":"Epilepsy Res."},{"year":"2012","series-title":"The Epilepsies: the Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care","author":"Freeman","key":"10.1016\/j.eplepsyres.2018.07.011_bib0065"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-1211(97)00025-9","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy","volume":"27","author":"Guerreiro","year":"1997","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1528-1167.2009.02331.x","article-title":"Comparison of antiepileptic drug prescribing in children in three European countries","volume":"51","author":"Hsia","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0095","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1046\/j.1528-1157.2002.t01-1-26901.x","article-title":"Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures","volume":"43","author":"Kotsopoulos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2012.02.019","article-title":"Utilization of antiepileptic drugs in Hong Kong children","volume":"46","author":"Kwong","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Landmark","year":"2011","journal-title":"Epilepsy Res."},{"year":"2016","series-title":"Richtlijn Epilepsie","author":"Majoie","key":"10.1016\/j.eplepsyres.2018.07.011_bib0110"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0120","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/pds.722","article-title":"Pharmacy data in epidemiological studies: an easy to obtain and reliable tool","volume":"11","author":"Monster","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2013.09.007","article-title":"Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010","volume":"23","author":"Pickrell","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0140","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-008-0480-z","article-title":"Antiepileptic drug utilization in children from 1997\u20132005--a study from the Netherlands","volume":"64","author":"van de Vrie-Hoekstra","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"year":"2006","series-title":"Epilepsie. Richtlijn Voor Diagnostiek En Behandeling","author":"van Donselaar","key":"10.1016\/j.eplepsyres.2018.07.011_bib0155"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erp.13.20","article-title":"The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges","volume":"13","author":"Visser","year":"2013","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2010.07.004","article-title":"RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology","volume":"91","author":"Weijenberg","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","article-title":"Levetiracetam monotherapy in children with epilepsy: a systematic review","volume":"29","author":"Weijenberg","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2018.07.011_bib0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/epi4.12024","article-title":"Investigator-initiated randomized controlled trials in children with epilepsy: mission impossible?","volume":"2","author":"Weijenberg","year":"2017","journal-title":"Epilepsia Open"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118301773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118301773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:39:30Z","timestamp":1760276370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118301773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"alternative-id":["S0920121118301773"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.011","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiepileptic drug prescription in Dutch children from 2006\u20132014 using pharmacy-dispensing data","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}